ENZ Logo

Enzo Biochem, Inc. (ENZ) 

NYSE
Market Cap
$58.77M
Sector
Healthcare
Industry
Medical—Diagnostics & Research
Rank in Sector
361 of 776
Rank in Industry
22 of 42

Largest Insider Buys in Sector

ENZ Stock Price History Chart

ENZ Stock Performance

About Enzo Biochem, Inc.

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, …

Insider Activity of Enzo Biochem, Inc.

Over the last 12 months, insiders at Enzo Biochem, Inc. have bought $0 and sold $0 worth of Enzo Biochem, Inc. stock.

On average, over the past 5 years, insiders at Enzo Biochem, Inc. have bought $261,776 and sold $2.09M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 10,000 shares for transaction amount of $12,875 was made by Wolf James G. () on 2023‑02‑13.

List of Insider Buy and Sell Transactions, Enzo Biochem, Inc.

2023-02-13Purchase
10,000
0.0208%
$1.29$12,875+10.83%
2023-02-10Purchase
5,000
0.0103%
$1.29$6,450+9.30%
2023-01-27Purchasedirector
11,800
0.024%
$1.40$16,5200.00%
2022-11-23PurchaseChief Executive Officer
100,000
0.2052%
$1.97$197,000-24.37%
2022-11-01Purchasedirector
8,500
0.0172%
$2.14$18,225-28.57%
2022-10-31Purchasedirector
14,500
0.0299%
$2.15$31,175-27.57%
2022-07-15PurchaseChief Operating Officer
2,500
0.0052%
$2.42$6,050-9.17%
2022-07-12Purchase
12,500
0.0243%
$2.27$28,375-9.17%
2022-07-05Purchase
120,000
0.2362%
$2.20$264,000-4.78%
2022-06-15Purchase
75,000
0.1523%
$2.20$165,000-1.35%
2022-06-15PurchaseChief Executive Officer
4,600
0.0093%
$2.19$10,074-1.35%
2022-06-14PurchaseChief Financial Officer
3,500
0.0074%
$2.15$7,525+4.76%
2021-03-16Sale10 percent owner
300,000
0.706%
$4.65$1.39M-19.61%
2021-03-15Sale10 percent owner
144,768
0.4879%
$4.83$698,840+10.81%
2020-02-18Purchase10 percent owner
4,000
0.0082%
$2.20$8,800+7.14%
2020-02-14Purchase10 percent owner
6,000
0.0125%
$2.21$13,260+7.66%
2019-08-20Purchase10 percent owner
9,700
0.0202%
$3.11$30,167-16.24%
2019-08-16Purchase10 percent owner
22,800
0.0456%
$3.06$69,768-18.32%
2019-07-23Purchase10 percent owner
409,200
0.87%
$3.65$1.49M-24.93%
2019-07-22Purchase10 percent owner
9,644
0.0201%
$3.64$35,104-26.36%

Insider Historical Profitability

<0.0001%
HARBERT MANAGEMENT CORP10 percent owner
5175913
9.9072%
$1.1382<0.0001%
Radoff Bradley Louis
4194663
8.029%
$1.1330<0.0001%
Wolf James G.
4100000
7.8478%
$1.1350<0.0001%
RABBANI ELAZARChm of the Bd, CEO and Sec
1848668
3.5385%
$1.1323+1.13%
RABBANI SHAHRAM KTreasurer, Secretary
1828494
3.4999%
$1.1315<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
HARBERT FUND ADVISORS, INC.$6.57M10.065.18M0%+$04.77
Renaissance Technologies$3.09M4.732.44M-1.78%-$55,970.810.01
The Vanguard Group$2.38M3.651.88M0%+$0<0.0001
Tang Capital Management, LLC$1.6M2.451.26M-25.88%-$558,783.660.01
BlackRock$1.21M1.85953,991+0.03%+$411.48<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.